Due Diligence Checklist
Life Sciences Due Diligence Checklist
Reverse Mergers and SPACs: Are APOs the New Norm for Biotechs Going Public?
Valuation of Your Early Drug Candidate
Preparing Your Company for the M&A Process
The Art & Science of High M&A Valuation
Best Practices for Fundraising and M&A Due Diligence
This whitepaper explores the importance of establishing early goals and objectives for the process, how to get the right people to ask the right questions in advance of the process, how to build credibility by defining goals and demonstrating they can be achieved, and much more.
Must-Know Finance Concepts for Life Sciences Valuations - Part II
This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value.
Demystifying Tech M&A Valuation
This whitepaper shares the most common scenarios that arise when you are selling your company, the choices you have when negotiating the terms of the sale, and which choices are your best ones, as supported by academic research are covered.
Must-Know Finance Concepts for Life Sciences Valuations